Seattle, Wash. • (206) 838-0500 • www.trubion.com
Exchange and Ticker: Nasdaq: TRBN
Filing Range: 4M shares @ $13 to $15
Offering Price: $13
Close on First Day: $13.10
Offering Size: $52M
Shares Outstanding: 16.9M
Underwriter: Morgan Stanley
Co-managers: Lazard Capital Markets/Banc of America Securities/Pacific Growth Equities Inc.
Company Counsel: Wilson Sonsini Goodrich & Rosati
Manager Counsel: Davis Polk & Wardwell
Auditor: Ernst & Young LLP
Market Capitalization on 10/31/06: $228.2M
Close price at current month end: $13.50
The company (f.k.a. GeneCraft Inc.) focuses on immunotherapeutics, developing a proprietary platform for inflammatrion and oncology therapeutics. The company has established a licensing and research agreement with Pacific Northwest Research Institute on a proprietary technology to discover novel single chain antibody therapeutics. The competition includes Genentech, Biogen Idec, Roche, Bristol-Myers Squibb, Amgen, Wyeth, JNJ, Shering-Plough, Abbo, GenMab, Immunomedics and Chugai.
Prospect Venture Partners, ARCH Venture Partners, Venrock Associates, Frazier Healthcare and Technology Ventures, Oxford Bioscience Partners and ATP Capital.
Source: Thomson Financial